Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Embla Medical hf has the GF Score of 92, which implies that the company
might have
Highest outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Embla Medical hf
might have
Highest outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Embla Medical hf (OCSE:EMBLA) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Embla Medical hf GF Score Related Terms
OCSE:EMBLA vs ABT, SYK, MDT: GF Score Comparison
For the Medical Devices subindustry, Embla Medical hf's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf GF Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's GF Score distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's GF Score falls into.
Embla Medical hf (OCSE:EMBLA) has a GF Score of 92 as of Jul. 22, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Embla Medical hf and its competitors. This is 14% above median its historical median of 81.00. Over the past decade, Embla Medical hf's GF Score has ranged from 58.00 to 96.00.
Is Embla Medical hf's GF Score too high?
Embla Medical hf's current GF Score of 92 is 14% above median its 10-year median of 81.00. Over the past 10 years, this metric has ranged from a low of 58.00 to a high of 96.00. Overall, Embla Medical hf has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's GF Score compare to ABT and SYK?
Embla Medical hf's GF Score of 92 can be compared against companies in the Medical Devices & Instruments industry. Historically, Embla Medical hf's own GF Score has ranged from 58.00 to 96.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Devices & Instruments company?
A good GF Score depends on the Medical Devices & Instruments industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Embla Medical hf and its competitors. Embla Medical hf's current GF Score is 92, which is 14% above median its own 10-year median of 81.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Based on GuruFocus' analysis, Embla Medical hf (OCSE:EMBLA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr34.07, compared to a current price of kr27.25 — trading 20% below its estimated fair value. The current GF Score is 92, which is 14% above median its 10-year median of 81.00. Embla Medical hf's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Embla Medical hf (OCSE:EMBLA), the current GF Score is 92 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OCSE:EMBLA) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of kr27.25 is trading 20% below its estimated GF Value™ of kr34.07.
GuruFocus considers Embla Medical hf to be Modestly Undervalued.
Key valuation signals for OCSE:EMBLA:
GF Score: 92 (14% above median its 10-year median of 81.00)
GF Value™: kr34.07 vs. price of kr27.25 (20% below fair value)
No single metric tells the full story. See the OCSE:EMBLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score
Get the complete analysis for OCSE:EMBLA
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:EMBLA has been successfully added to your 
